Drug intelligence / Profile preview

CG223

Development stage: Preclinical
Lead developer: ConverGene
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

CG223 is a small molecule dual inhibitor that targets both BET bromodomains (specifically BRD4) and the dopamine receptor D2 (DRD2). Developed by ConverGene as the lead candidate in their CVG101 program, CG223 is designed to address the complex signaling pathways in solid tumors and hematologic malignancies, including acute myeloid leukemia (AML). By simultaneously inhibiting epigenetic readers and G-protein coupled receptor signaling, the compound aims to overcome resistance mechanisms common in monotherapies. As of 2024, CG223 has progressed to IND-enabling studies and pre-clinical toxicology testing.

Other names: CG223/CG250

Targets

BRD3 (Bromodomain-containing protein 3)BRDT (Bromodomain testis-specific protein)BRD4 (Bromodomain-containing protein 4)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on CG223.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG223.

Explore the full profile